AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

3/26/24 9:05:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $AIM alert in real time by email

OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET.

The call will be hosted by members of AIM's leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company's website, aimimmuno.com, and will be archived for 90 days following the live event.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
[email protected]

Get the next $AIM alert in real time by email

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

Chat with this insight

Recent Analyst Ratings for
$AIM

$AIM
Press Releases

Fastest customizable press release news feed in the world

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

$AIM
SEC Filings

AIM ImmunoTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

AIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form DEF 14A filed by AIM ImmunoTech Inc.

$AIM
Leadership Updates

Live Leadership Updates

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members

Kellner Group Announces Support from Another Former AIM Senior Executive

$AIM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

$AIM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group resumed coverage on AIM ImmunoTech with a new price target

$AIM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

$AIM
Financials

Live finance-specific insights

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

$AIM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

SEC Form SC 13G filed by AIM ImmunoTech Inc.

Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

Chat with this insight

Recent Analyst Ratings for $AIM

$AIM Press Releases

Fastest customizable press release news feed in the world

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

$AIM SEC Filings

AIM ImmunoTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

AIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form DEF 14A filed by AIM ImmunoTech Inc.

$AIM Leadership Updates

Live Leadership Updates

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members

Kellner Group Announces Support from Another Former AIM Senior Executive

$AIM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

$AIM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group resumed coverage on AIM ImmunoTech with a new price target

$AIM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

$AIM Financials

Live finance-specific insights

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

$AIM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

SEC Form SC 13G filed by AIM ImmunoTech Inc.

Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

Recent Analyst Ratings for
$AIM

$AIM
Press Releases

$AIM
SEC Filings

$AIM
Leadership Updates

$AIM
Insider Purchases

$AIM
Analyst Ratings

$AIM
Insider Trading

$AIM
Financials

$AIM
Large Ownership Changes